Q-omics provides the consensus-scored TCF15 profile across patient tissues and cancer cell-line models. TCF15 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, TCF15 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TCF15 RNA expression shows 15,076 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LAML, HNSC, and LSCC as cancer lineages where TCF15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF15 survival associations across molecular data types. TCF15 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF15 RNA expression–survival associations across cancer types. High TCF15 expression shows unfavorable associations in LAML, KIRP, OV and UCS, but favorable associations in UCEC and LUSC. The LAML Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for TCF15 RNA expression.
This table summarizes TCF15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TCF15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF15 shows lower tumor expression in BRCA, LUAD and KICH and higher tumor expression in HNSC, LIHC and LUSC. The HNSC box plot shows higher TCF15 RNA expression in tumor versus normal tissue (log2 FC = +0.631, t-test p < 0.001).
This table shows molecular features associated with TCF15 in patient tissues and cancer cell lines. In patient samples, TCF15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
